Magnesium Sulfate Sterop (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as calcium antagonists. By competing with calcium at voltage‑gated channels, it causes vasodilation, reduces neuronal excitability, relaxes smooth muscle, and stabilises cardiac cell membranes, which together help prevent seizures, uterine contractions, and abnormal heart rhythms.

The dosage of Magnesium Sulfate Sterop is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Healthcare professionals set the infusion rate and total amount according to established treatment protocols.

Magnesium sulfate is commonly used in obstetric care for eclampsia and tocolysis, but its use should be guided by an obstetrician. Limited data are available for breastfeeding, and the decision should consider the benefit‑risk balance for mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with other tocolytics such as nifedipine or atosiban, magnesium sulfate has a well‑established safety record for short‑term use in preterm labor and also offers anticonvulsant benefits for eclampsia. However, it may cause more pronounced hypotension and requires careful monitoring of serum magnesium levels.

Magnesium Sulfate Sterop should be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Inspect the product before use for any particulate matter or discoloration.

The product is supplied as a sterile injection solution for intravenous infusion. It is administered by a qualified healthcare professional through a controlled IV line, with infusion rates adjusted according to the clinical protocol and patient monitoring parameters.

The most serious risks include respiratory depression, severe hypotension, cardiac arrest due to hypermagnesemia, and rare anaphylactoid reactions. Continuous monitoring of respiratory function, blood pressure, and serum magnesium levels is essential during therapy.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without dialysis, uncontrolled cardiac conduction disorders, or those receiving high‑dose calcium‑containing solutions should not receive Magnesium Sulfate Sterop unless a specialist determines that benefits outweigh the risks.